Nkiru Odinkemelu
The new management of Swiss Pharma Nigeria Limited (Swipha) has said it was committed to doing all it takes to maintain and strengthen its position as a pharmaceutical leader.
Towards achieving these goals, the company said it has set in motion a restructuring process focusing on innovation, staff training, new and compliant processes and business practices in order to offer a large range of efficient products of quality to patients in the country and the West African sub-region.
In March 2017, Biogaran, a subsidiary of Servier, a French Pharmaceutical Group that specialises in generics, acquired Swipha as part of its expansion plans to other African countries and to increase local production and distribution of drugs in the country.
The management, in a press release signed by Gaby El Khoury, Managing Director, Swiss Pharma Nigeria Limited, noted that to further reposition Swipha to meet global standards, it was introducing fresh ideas to improve on the welfare of staff as well as new corporate policies, with the view to attracting and retaining talented and motivated staff at every level.
He said: ”A first move from the Management is to reshape the functions of its field force, in line with global standards to exceed the expectations of her esteemed customers.
“Swipha strongly believes in Nigeria and is committed to its economic and moral development and will engage in global best practices. It is committed to doing all it takes to ensure that it maintains and strengthens its position as a leader in the pharmaceutical sector.”